Humalog Mix 50 Kwikpen Injection
Insulin Lispro (25%/50%) + Insulin Lispro Protamine (75%/50%) mix
100 Units/ml
LILLY FRANCE SA
| Pack size | 3ml Pre-filled Pen x 5 |
|---|---|
| Dispensing mode | POM |
| Source | FRANCE |
| Agent | PHARMATRADE |
| Retail Price | 231.00 AED |
Available as:
Indications
Humalog Mix 50 Kwikpen Injection is used for:
Diabetes mellitus
Adult Dose
Subcutaneous
Diabetes Mellitus
Combination rapid-onset (faster than regular insulin) and intermediate-acting insulins in fixed dose
Dose regimen varies among patients depending on metabolic needs; typical daily insulin requirements range between 0.5-1 unit/kg
Initially, 10 units with the largest meal of the day, dose adjustments may be made on a wkly basis according to blood glucose levels.
Dose should not be increased if there is hypoglycaemic episode (<70 mg/dl) during a 3-day period.
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment: Dose adjustments may be required.
Administration
Administer SC BID (ie, before breakfast and evening meal); each dose intended to cover 2 meals or a meal and snack
Inject SC into abdominal wall, thigh, or upper arm
Contra Indications
Hypoglycaemia. Hypersensitivity to any of the components.
Precautions
Renal or hepatic impairment; pregnancy, lactation; transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections.
Lactation: Unknown whether distributed in breast milk; compatible with breast feeding, but lactating women may require dosage adjustment; caution advised
Pregnancy-Lactation
Pregnancy
The limited available data in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes; published studies during pregnancy have not reported association between drug and induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes; there are risks to mother and fetus associated with poorly controlled diabetes in pregnancy
Poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications; also increases fetal risk for major birth defects, still birth, and macrosomia related morbidity
Animal data
Pregnant rats and rabbits exposed to drug during organogenesis showed no adverse effects on embryo/fetal viability or morphology in offsprings administered a dose approximately 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day; no adverse effects on embryo/fetal development were observed in offspring of rabbits exposed to insulin lispro at doses up to approximately 0.24 times the human subcutaneous dose of 1 unit/kg/day
Lactation
There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; one small published study reported exogenous insulin present in human milk; however, there is insufficient information to determine effects on breastfed infant and no available information on the effects on milk production; the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for insulin, any potential adverse effects on breastfed child from drug or from underlying maternal condition
Interactions
Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by beta-blockers, clonidine.
Adverse Effects
Side effects of Insulin Lispro (25%/50%) + Insulin Lispro Protamine (75%/50%) mix :
Hypoglycaemia; hypokalemia, oedema; pruritus; pulpitation, nausea, rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj.
Mechanism of Action
Insulin lispro is a short-acting biosynthetic human insulin analogue. Insulin lispro protamine is an intermediate-acting glucose-lowering agent; it is a suspension of crystals produced from combining insulin lispro and protamine sulfate under appropriate conditions for crystal formation. They are used together for the regulation of glucose metabolism.
Note
Humalog Mix 50 Kwikpen 100 Units/ml Injection manufactured by LILLY FRANCE SA. Its generic name is Insulin Lispro (25%/50%) + Insulin Lispro Protamine (75%/50%) mix. Humalog Mix 50 Kwikpen is availble in United Arab Emirates.
Farmaco UAE drug index information on Humalog Mix 50 Kwikpen Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.